ICAAC 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Sept 17-20, 2007 Chicago, ILL.<br>

Conference Reports for NATAP


ICAAC 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Sept 17-20, 2007 Chicago, ILL.

	Antiretroviral Therapy at 47th ICAAC 2007 (Sept 2007): RTV-boosted PIs in treatment-naives; CCR5 antagonists; integrase inhibitors - written by Eric S. Daar, M.D. - (10/02/07) In Vitro Antiviral Potency and Preclinical Pharmacokinetics of GSK364735 Predict Clinical Efficacy in a Phase 2a Study - (10/01/07) GSK364735 is a Potent Inhibitor of HIV Integrase and Viral Replication - (10/01/07) Resistance Mechanisms of the K70E HIV-1 Reverse Transcriptase Mutant to GS-9148 and Other NRTIs - (10/01/07) Novel 2'-Fluoro Substituted Nucleotide HIV Reverse Transcriptase Inhibitor GS-9148 Exhibits Low Potential for Mitochondrial Toxicity In Vitro - (10/01/07) Novel Nucleotide Inhibitor GS-9148 Selects for a K70E Mutation in HIV-1 Reverse Transcriptase and Low-Level Resistance In Vitro - (10/01/07) Interrupting antiretroviral therapy does not reduce CVD risk and activates the immune system - (09/28/07) Efficacy and Safety of Protease Inhibitor Replacemet for Nevirapine In Patients with High CD4 Lymphocyte Cell Counts: A Systematic Review - (09/28/07) Prediction of disease progression by HIV co-receptor tropism (CRT) in persons (P) with untreated chronic HIV infection - (09/27/07) Co-receptor Tropism Predictions Based on V3 Loop Sequence in Antiretroviral-Experienced Patients are Specific but Insensitive for the Detection of CXCR4-using Variants - (09/27/07) Enhancements to the Trofile™ HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations - (09/27/07) Abacavir-Containing HAART Reduces the Chances for Sustained Virological Response to Pegylated-Interferon pllus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C - (09/26/07) Antiviral Effects and Tolerability of the CCR5 Monoclonal antibody PRO 140: A Proof of Concept Study in HIV-Infected Individuals - (09/25/07) Cancer Rates Higher in HIV+, CD4s Lower - (09/25/07) Lopinavir (LPV) Cerebrospinal Fluid (CSF) Trough Concentrations in HIV-infected Adults - (09/25/07) Pharmacokinetics of TMC125 in HIV-negative volunteers with mild or moderate hepatic impairment - (09/25/07) Raltegravir (RAL) Dose Proportionality and Effect of Food - (09/24/07) Limb Fat Increased by 25% 3 Years After Switch to TDF from d4T - (09/24/07) Development of resistance in patients with virologic failure (VF) on darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r): results of a randomized, controlled, Phase III trial in treatment-experienced patients (TITAN) - (09/19/07) The HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) - (09/19/07) Efficacy and Safety of Darunavir/ritonavir versus Lopinavir/ritonavir in ARV Treatment-Naive HIV-1-Infected Patients at Week 48: ARTEMIS (TMC114-C211) - (09/19/07) Efficacy and Safety of Maraviroc in Antiretroviral-Experienced Patients Infected With CCR5-Tropic HIV-1: 48-Week Results of MOTIVATE 1 - (09/19/07) Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials - (09/19/07) Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) versus placebo in treatment-experienced HIV-1-infected patients - (09/19/07) 48 Week Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus, Phase II Protocol 005 - (09/19/07) Studies Highlight Superior Performance of Trofile(TM) Assay - (09/19/07) Two-Year Follow-up of Treatment-Experienced Patients on Vicriviroc (VCV) - (09/19/07) New HIV Drugs, Final Oral Slide Session at ICAAC 2007 - (09/19/07) Fosamprenavir or Atazanavir Boosted with Ritonavir Given Once Daily with Tenofovir /Emtricitabine in Antiretroviral Naive HIV-Infected Patients: ALERT Study Virology Analysis Through 48 Weeks - (09/17/07) Clinical Presentation of Hypersensitivity Reaction to Abacavir (ABC HSR) by HLA-B*5701 Status - (09/17/07) Long-term Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/r) Versus Lopinavir/Ritonavir (LPV/r) over 96 Weeks - (09/17/07)